RxDoctor Payments Data

Shane Ashford, DO

Family Medicine · Denton, TXNPI 1518144534

Payments from drug & device makers

$18,199in general payments, 2019–2025

Across 1,155 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$1K
  • Amgen$1K
  • Lilly USA, LLC$954
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$18,06799%
  • Education$1311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk187$2,458
AstraZeneca106$1,738
AbbVie(2 entities)106$1,615
GSK65$1,166
Amgen75$1,034
Lilly USA, LLC66$954
Pfizer45$750
Otsuka America Pharmaceutical, Inc.40$709
Johnson & Johnson38$592
Bayer36$577
Boehringer Ingelheim30$497
Sanofi-aventis U.S. LLC25$467
Astellas Pharma US Inc15$360
Merck21$318
Takeda Pharmaceuticals U.S.A., Inc.17$311
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$290
Amarin Pharma, Inc.18$279
Novartis12$275
Exact Sciences19$272
Antares Pharma, Inc.11$230
Dexcom, Inc.13$227
Axsome Therapeutics, Inc.7$184
Lundbeck LLC14$179
Corcept Therapeutics9$169
Abbott16$166
Sunovion Pharmaceuticals Inc.19$160
Phathom Pharmaceuticals, Inc.9$156
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$149
Sumitomo Pharma America, Inc.7$131
Sanofi Pasteur Inc.9$128
Teva Pharmaceuticals USA, Inc.7$107
Shield Therapeutics Inc2$103
Nevro Corp.5$93
Radius Health, Inc.5$92
Biohaven Pharmaceutical Holding Company Ltd.3$63
Tris Pharma Inc3$59
Esperion Therapeutics, Inc.3$58
Nalpropion Pharmaceuticals LLC4$56
IBSA Pharma Inc.3$55
Pacira Therapeutics, Inc.3$55
Currax Pharmaceuticals LLC4$53
Alnylam Pharmaceuticals Inc.3$53
Ironwood Pharmaceuticals, Inc4$52
Aimmune Therapeutics, Inc.3$52
Valeritas, Inc.2$51
Eisai Inc.3$51
Dynavax Technologies Corporation3$47
Pacira Pharmaceuticals Incorporated2$43
Biohaven Pharmaceuticals, Inc.3$41
Seqirus USA Inc2$38
Vivus LLC2$36
Arbor Pharmaceuticals, Inc.2$34
Biogen2$33
Nestle Healthcare Nutrition Inc.2$33
Medtronic(2 entities)2$28
Inari Medical, Inc.1$26
Mylan Specialty L.p.1$25
Shire North American Group Inc2$25
Inspire Medical Systems, Inc.1$25
Amneal Pharmaceuticals LLC1$22

How this compares

$18,199 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$258,331
Medicare patients
592
Services billed
4,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$282,443
JardianceEmpagliflozin161$170,200
Repatha SureclickEvolocumab134$121,672
MounjaroTirzepatide84$105,184
JanuviaSitagliptin Phosphate91$96,258
EliquisApixaban99$93,028
TrulicityDulaglutide71$91,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$80,531
XareltoRivaroxaban45$70,667
FarxigaDapagliflozin Propanediol50$47,649
RybelsusSemaglutide33$46,499
MyrbetriqMirabegron80$43,264
ProliaDenosumab23$40,216
TradjentaLinagliptin30$40,053
LinzessLinaclotide48$36,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,458$328,941202 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$497$222,831204 claims
Lilly USA, LLCMounjaro, Trulicity$954$197,099155 claims
GSKTrelegy Ellipta, Anoro Ellipta, Lamictal, Breo Ellipta$1,166$131,790142 claims
MerckJanuvia$318$96,25891 claims
PfizerEliquis$750$93,02899 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,738$87,267129 claims
Johnson & JohnsonXarelto$592$70,66745 claims
Astellas Pharma US IncMyrbetriq$360$43,26480 claims
AbbVieLinzess, Synthroid$1,615$41,947161 claims
AmgenProlia$1,034$40,21623 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$467$22,35730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →